Literature DB >> 17884351

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.

Georg Juckel1, Patrik Roser, Thomas Nadulski, Andreas M Stadelmann, Jürgen Gallinat.   

Abstract

Reduced amplitudes of auditory evoked mismatch negativity (MMN) have often been found in schizophrenic patients, indicating deficient auditory information processing and working memory. Cannabis-induced psychotic states may resemble schizophrenia. Currently, there are discussions focusing on the close relationship between cannabis, the endocannabinoid and dopaminergic system, and the onset of schizophrenic psychosis. This study investigated the effects of cannabis on MMN amplitude in 22 healthy volunteers (age 28+/-6 years, 11 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol (CBD) in a prospective, double-blind, placebo-controlled cross-over design. The MMNs resulting from 1000 auditory stimuli were recorded by 32 channel EEG. The standard stimuli were 1000 Hz, 80 dB SPL, and 100 ms duration. The deviant stimuli differed in frequency (1500 Hz). Significantly greater MMN amplitude values at central electrodes were found under cannabis extract, but not under Delta(9)-THC. There were no significant differences between MMN amplitudes at frontal electrodes. MMN amplitudes at central electrodes were significantly correlated with 11-OH-THC concentration, the most important psychoactive metabolite of Delta(9)-THC. Since the main difference between Delta(9)-THC and standardized cannabis extract is CBD, which seems to have neuroprotective and anti-psychotic properties, it can be speculated whether the greater MMN amplitude that may imply higher cortical activation and cognitive performance is related to the positive effects of CBD. This effect may be relevant for auditory cortex activity in particular because only MMN amplitudes at the central, but not at the frontal electrodes were enhanced under cannabis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884351     DOI: 10.1016/j.schres.2007.08.015

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

1.  Delayed preattentional functioning in early psychosis patients with cannabis use.

Authors:  Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2012-03-09       Impact factor: 4.530

Review 2.  How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.

Authors:  J Leon Kenemans; Seppo Kähkönen
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

3.  Auditory mismatch negativity deficits in long-term heavy cannabis users.

Authors:  Patrik Roser; Beate Della; Christine Norra; Idun Uhl; Martin Brüne; Georg Juckel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-02       Impact factor: 5.270

Review 4.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

5.  Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.

Authors:  Michael A Taffe; Kevin M Creehan; Sophia A Vandewater
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

6.  Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Authors:  Patrik Roser; Jürgen Gallinat; Gordon Weinberg; Georg Juckel; Inge Gorynia; Andreas M Stadelmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

7.  Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol.

Authors:  M Jerry Wright; Sophia A Vandewater; Michael A Taffe
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains.

Authors:  L Cinnamon Bidwell; Raeghan Mueller; Sophie L YorkWilliams; Sarah Hagerty; Angela D Bryan; Kent E Hutchison
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01

Review 9.  The early identification of psychosis: can lessons be learnt from cardiac stress testing?

Authors:  Swapnil Gupta; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2015-11-14       Impact factor: 4.530

10.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Authors:  Margaret Haney; Robert J Malcolm; Shanna Babalonis; Paul A Nuzzo; Ziva D Cooper; Gillinder Bedi; Kevin M Gray; Aimee McRae-Clark; Michelle R Lofwall; Steven Sparenborg; Sharon L Walsh
Journal:  Neuropsychopharmacology       Date:  2015-12-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.